Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Clinical Research Fellow at Dana-Farber Cancer Institute, Visiting Professor at McGill University, shared a post on LinkedIn:
“2025: quite a year for ADCs in breast cancer
- T-DXd approved for 1L cytotoxic tx of HR+/HER2-low (and ultralow) MBC
- T-DXd now also approved for 1L HER2+ MBC
- First positive phase 3 data of T-DXd in the CURATIVE setting
- Two TROP2 ADCs replaced 1L SoC in mTNBC
Keep them coming, 2026.”
More posts featuring Paolo Tarantino on OncoDaily.